Catalent Inc

NYSE: CTLT
$60.59
-$0.12 (-0.2%)
Closing Price on October 4, 2024

CTLT Stock Chart and Intraday Price

CTLT Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, US
Fiscal Year End June
Latest Quarter 12/31/2023
Market Cap 10,336.41M USD
Shares Outstanding 180,738,000
Catalent Inc is a global leader in providing integrated services, superior drug delivery technologies, and manufacturing solutions to help life science innovators develop and launch successful pharmaceuticals, biologics, and consumer health products. With expertise in oral, nasal, inhaled, and topical formulations, as well as biologic and gene therapies, Catalent supports clients across the pharmaceutical, biotechnology, and consumer health sectors. Its offerings include advanced formulation, development, and clinical supply services, ensuring products reach the market faster and more efficiently. Founded in 1933, Catalent is headquartered in Somerset, New Jersey, serving companies worldwide.

CTLT Articles

Tuesday morning economic news did not include big changes in either the consumer confidence index, down about 1.5 points month over month but still above 100, or the employment cost index, up by...
Wednesday's top analyst upgrades and downgrades included American Express, Catalent, Centene, Lowe's Companies, NetApp, Shoals Technologies, Valley National Bancorp and ZoomInfo Technologies.
Friday's top analyst upgrades and downgrades included Activision Blizzard, Arista Networks, Cadence Design Systems, Carvana, Cisco Systems, Estee Lauder, Host Hotel & Resorts, Intel, Kosmos Energy,...
Thursday's top analyst upgrades and downgrades included Albemarle, Catalent, Chipotle Mexican Grill, Cinemark, CrowdStrike, DoorDash, Estee Lauder, Icahn Enterprises, McDonald's, ServiceNow and...
Late Thursday, a major supplier of the machines that fabricate computer chips will report earnings. Early Friday, a heavy equipment maker, a contract drug maker and a shoe retailer will follow suit.